HANGES IN AND INTERRELATIONSHIPS BETWEEN BLOOD SERUM INTERLEUKIN-2, INTERLEUKIN-6, AND TUMOR NECROSIS FACTOR- UPON LIVER CIRRHOSIS OF VIRAL ETIOLOGY
https://doi.org/10.22328/2077-9828-2017-9-2-42-46
Abstract
ELISA was used to assess serum levels of interleukin-2 (IL-2), interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) in liver cirr- hosis patients referred to Child-Pugh Classes A, B, and C. Increasing the grade of liver cirrhosis was associated with a trend to increa- ses in serum IL-2, IL-6 and TNF-a within reference values, except for IL-6 in Class C patients whose sera contained 14,89±4,96 pg/ml IL-6 (range: 9,94 to 25,21 pg/ml), which is above reference values. Class A cirrhosis features a negative correlation between TNF-a and IL-6 levels (r=-0,421), whereas Class B cirrhosis features a positive correlation between TNF-a and IL-2 (r=0,421).
About the Authors
B. B. FishmanRussian Federation
V. V. Zurabov
Russian Federation
V. Ye. Kulikov
Russian Federation
M. E. Hapman
Russian Federation
M. A. Toneyeva
Russian Federation
S. Sh. Butrimova
Russian Federation
References
1. Голованова Е.В. Механизмы фиброзообразования при хронических заболеваниях печени и возможности антифибротической терапии // Гастроэнтерология. 2014. № 8. С. 52–59. [Golovanova E.V. Mechanisms of fibrocavitory in chronic liver disease and possible antifibrotics the- rapy. Gastroenterology, 2014, No. 8, рр. 52–59 (In Russ.)].
2. Назыров Ф.Г., Девятов А.В., Бабаджанов А.Х., Раимов С.А. Особенности развития и течения осложнений цирроза печени в зависимости от этиологического фактора // Новости хирургии. 2013. № 4. С. 45–50. [Nazyrov F.G., Deviyatov A.V., Babadzhanov A.H., Raimov S.A. Рeculiarities of development and course of complications of liver cirrhosis depending on the etiological factor. News Surgery, 2013, No. 4, pp. 45– 50 (In Russ.)].
3. Филиппова Л.П., Белобородова Э.И., Белобородова Е.В., Алексеева А.С. Качество жизни больных циррозом печени в зависимости от тонуса вегетативной нервной системы // Бюллетень сибирской медицины. 2012. № 4. С. 152–157. [Filippova L.P., Beloborodova E.I., Beloborodova E.V., Alekseeva A.S. Quality of life in patients with liver cirrhosis depending on the tone of the autonomic nervous system. Bulletin of Siberian Medicine, 2012, No. 4, pp. 152–157 (In Russ.)].
4. Iwakir Y., Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology, 2006, Vol. 43, Suppl. 1, рр. 122–130.
5. Шерлок Ш.М., Дули Дж. Заболевания печени и желчных путей. М.: Медицина, 1999, 115 с. [ Sherlock Sh.M., Dooley J. Diseases of the liver and biliary tract. Moscow: Medicine, 1999, 115 p. (In Russ.)].
6. Laleman W., Landeghem L.V., Wilmer А.А. Portal hypertension: from pathophysiology to clinical practice. Liver Int., 2005, Vol. 25, рр. 1080–1089.
7. Giannitrapani L., Soresi М., Balasus D. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepato- cellular carcinoma. World J. Gastroenterol., 2013, Vol. 19, No. 16, рр. 2449–2455.
8. Ивашкин В.Т., Мамаев С.Н., Лукина Е.А. Особенности иммунного ответа у больных хроническим вирусным гепатитом С // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2001. № 3. С. 24–28. [Ivashkin V.T., Mamaev S.N., Lukina E.A. The peculiarities of immune response in patients With chronic hepatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2001, No. 3, pp. 24– 28 (In Russ.)].
9. Мироджанов Г.К., Авезов С.А., Гиясов М.М., Абдуллаева З.М. Интерлейкин-6 и оксид азота в патогенезе портальной гипертензии и деком- пенсации цирроза печени // Клиническая медицина. 2012. № 1. C. 47–53. [Mirodzhanov G.K., Avezov S.A., Giyasov M.M., Abdullayeva Z.M. Interleukin-6 and nitric oxide in pathogenesis of portal hypertension and decompensation of cirrhosis of the liver. Clinical Medicine, 2012, No. 1, pp. 47–53 (In Russ.)].
10. Handa P., Kowdley K.V. Chemokines: potent mediators of hepatic inflammation and fibrosis in chronic liver diseases. Ann. Hepatol., 2014, Vol. 13, No. 1, рр. 152–154.
11. Li S., Huang X., Zhong H. Tumour necrosis factor alpha (TNF-) genetic polymorphisms and the risk of autoimmune liver disease: a meta-ana- lysis. J. Genet., 2013, Vol. 92, No. 3, рр. 617–628.
12. Fuster D., Tsui J.I., Cheng D.M. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol pro- blems. AIDS Res. Hum. Retroviruses, 2013, Vol. 29, No. 8, рр. 1110–1116.
13. Osawa Y., Hoshi M., Yasuda I. Tumor necrosis factor-promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metal- loproteinase-1 production in hepatic stellate cells. PLoS One, 2013, Vol. 8, No. 6, рр. 65251–65262.
14. Elsing С., Harenberg S., Stremmel W., Herrman T. Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic pati- ents. World J. Gastroenterol., 2007, Vol. 13, No. 3, рр. 421–425.
15. Ивашкин В.Т. Резистентный асцит у больных циррозами печени. М.: МЕДпресс-информ, 2013, 37 с. [Ivashkin V.T. Resistant ascites in pati- ents with liver cirrhosis. Moscow: MEDPress-Inform, 2013, 37 p. (In Russ.)].
16. Ивашкин В.Т. Осложнения портальной гипертензии при циррозе печени // Российский физиологический журнал. 2009. № 10. С. 74–76. [Ivashkin V.T. Complications of portal hypertension in liver cirrhosis. Russian Physiological Journal, 2009, No. 10, pp. 74–76 (In Russ.)].
17. Пальцев М.А., Кактурский Л.В., Зайратьянц О.В. Патологическая анатомия. М.: ГЭОТАР-Медиа, 2011. 1206 с. [Paltsev M.A., Kaktursky L.V., Zairatyants O.V. Pathological anatomy. Moscow: GEOTAR-Media, 2011, 1206 p. (In Russ.)].
18. Kоksal A.S., Köklű S., Ibic M. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 Turkish patients with hepatoportal scle- rosis. Dig. Dis. Sci., 2009, Vol. 52, No. 12, рр. 3494–3497.
19. Giannitrapani L., Soresi M., Balasus D. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepato- cellular carcinoma. World J. Gastroenterol., 2013, Vol. 19, No. 16, рр. 2449–2455.
20. Chen T.A., Sao Chen C. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand. J. Gastroenterol., 2009, Vol. 44, рр. 619–625.
21. Elsing С., Harenberg S., Stremmel W., Herrman T. Serum levels of soluble fas, nitric oxide and cytokines in acute decompensated cirrhotic pati- ents. World J. Gastroenterol., 2007, Vol. 13, No. 3, рр. 421–425.
22. Naveau S., Balian A., Degos F. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha. J. Herpatol., 1999, Vol. 31, No. 1, рр. 611–618.
23. Яковенко Э.П., Яковенко А.В., Каграманова А.В., Прянишникова А.С., Иванов А.Н. Современные подходы к терапии больных циррозом печени // Фарматека. 2012. № 13. С. 88–93. [Yakovenko E.P., Yakovenko A.V., Kagramanova A.V., Pryanishnikov A.S., Ivanov A.N. Modern approaches to the treatment of patients with liver cirrhosis. Farmateka, 2012, No. 13, pp. 88–93 (In Russ.)].
Review
For citations:
Fishman B.B., Zurabov V.V., Kulikov V.Ye., Hapman M.E., Toneyeva M.A., Butrimova S.Sh. HANGES IN AND INTERRELATIONSHIPS BETWEEN BLOOD SERUM INTERLEUKIN-2, INTERLEUKIN-6, AND TUMOR NECROSIS FACTOR- UPON LIVER CIRRHOSIS OF VIRAL ETIOLOGY. HIV Infection and Immunosuppressive Disorders. 2017;9(2):42-46. (In Russ.) https://doi.org/10.22328/2077-9828-2017-9-2-42-46